Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms (ATLAS)

3 novembre 2026 aggiornato da: Biogen

Uno studio di fase 3 randomizzato, controllato con placebo, con run-in di storia naturale longitudinale ed estensione in aperto per valutare BIIB067, avviato in adulti clinicamente presintomatici con una mutazione confermata della superossido dismutasi 1

In this study, researchers will learn more about the effects of a drug called tofersen, also known as BIIB067 and QALSODY®, in adults with amyotrophic lateral sclerosis (ALS) who have a superoxide dismutase 1 (SOD1) gene mutation.

One of the causes of ALS is a change (or mutation) in the SOD1 gene, which causes abnormal SOD1 protein to be made. This abnormal protein can cause the motor neurons in people with ALS to break down and die. When neurons are damaged, they release a protein called neurofilament light chain, also known as NfL. Previous studies have shown that NfL levels are higher in people with SOD1-ALS, even before any ALS symptoms appear.

In this study, researchers will look at the effect of tofersen treatment in the earlier stages of the disease, even before ALS symptoms appear. Researchers believe that giving tofersen to patients as early as possible may slow the onset of ALS symptoms and the progression of the disease.

This study will have 4 parts. In Part A, participants will have their health monitored and NfL levels tested on a monthly basis, but they will not receive any study drug. Tofersen or placebo will be given to participants in Parts B, while all participants will receive tofersen in Parts C and D.

The main question that researchers want to answer is:

• How long does it take for ALS symptoms to appear?

Researchers will also learn more about:

  • How many participants develop ALS symptoms within 24 months of the start of Part B
  • Changes in participants' ability to perform their daily activities
  • Changes in participants' ability to breathe
  • How many participants die or need long-term breathing support
  • Changes in NfL levels in the blood
  • Changes in SOD1 protein levels in the fluid around the brain and spinal cord
  • How many participants have adverse events or serious adverse events. Adverse events are health problems that may or may not be caused by the study drug.

The study will be done as follows:

  • Participants will first be screened to check if they can join the study. The screening period will be up to 6 weeks. Participants will join the study only after reading and signing an informed consent form, also known as an ICF.
  • In Part A, participants with presymptomatic ALS will not get any study drugs. Researchers will check the levels of NfL in their blood. Participants will be closely checked for any signs or symptoms of ALS.
  • Once a participant's NfL levels rise to a certain amount, they will move onto Part B.
  • In Part B, participants will be randomly assigned to get either tofersen or a placebo. Neither participants nor researchers will know who gets tofersen or the placebo during Part B. A placebo looks like the study drug but contains no medicine.
  • Participants will get the first 3 doses of tofersen once every 14 days. Afterwards, they will continue getting maintenance doses every 28 days.
  • All doses will be given through an intrathecal (IT) injection done through a lumbar puncture procedure. This involves injecting the drug into the fluid surrounding the spinal cord in the lower back.
  • Participants who develop ALS symptoms during Part B will move to Part C to receive tofersen.
  • Participants who develop ALS symptoms during Part A will move to Part D to receive tofersen.
  • In both Parts C and D, participants will know they are receiving tofersen.
  • Throughout the study, doctors will measure any changes to the participants' function and quality of life using different questionnaires. Doctors will also take blood and urine samples. They will also check the participants' overall health and ask how they are feeling.
  • Participants will have a follow-up visit 28 days after their last dose of study drug.
  • Participants will be in this study for up to about 6.5 years.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability of tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest ALS.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

158

Fase

  • Fase 3

Accesso esteso

Approvato per la vendita al pubblico. Vedi record di accesso esteso.

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • New South Wales
      • Macquarie Park, New South Wales, Australia, 2109
        • Macquarie University Hospital
      • Leuven, Belgio, 3000
        • UZ Leuven
      • São Paulo, Brasile, 04038-002
        • PSEG Centro de Pesquisa Clinica
    • São Paulo
      • São Paulo, São Paulo, Brasile, 04037-002
        • Hospital Sao Paulo
    • Alberta
      • Calgary, Alberta, Canada, T2N4Z6
        • University of Calgary
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Health Sciences Centre
    • Quebec
      • Montreal, Quebec, Canada, H4A 3T2
        • Genge Partners
      • Seoul, Corea del Sud, 04763
        • Hanyang University Seoul Hospital
    • Paris
      • Paris, Paris, Francia, 75651
        • Groupe Hospitalier Pitie-Salpetriere
    • Baden-Wurttemberg
      • Ulm, Baden-Wurttemberg, Germania, 89081
        • Universitaetsklinikum Ulm
    • Lower Saxony
      • Hanover, Lower Saxony, Germania, 30625
        • Medizinische Hochschule Hannover
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, Giappone, 890-8520
        • Kagoshima University Hospital
    • Tokyo-To
      • Bunkyō City, Tokyo-To, Giappone, 113-8655
        • University of Tokyo Hospital
      • Torino, Italia, 10124
        • Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
      • Warsaw, Polonia, 01-684
        • Centrum Medyczne NeuroProtect
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polonia, 01-684
        • NeuroProtect Sp. z o.o.
    • South Yorkshire
      • Sheffield, South Yorkshire, Regno Unito, S10 2RX
        • University of Sheffield
      • Valencia, Spagna, 46026
        • Hospital Universitari i Politecnic La Fe
    • Arizona
      • Scottsdale, Arizona, Stati Uniti, 85258
        • HonorHealth Neurology
    • California
      • La Jolla, California, Stati Uniti, 92093-0949
        • University of California San Diego Medical Center
      • San Francisco, California, Stati Uniti, 94107
        • California Pacific Medical Center Research Institute
    • Florida
      • Fort Lauderdale, Florida, Stati Uniti, 33308
        • Holy Cross Hospital
      • Miami, Florida, Stati Uniti, 33136
        • University of Miami School of Medicine
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322-4200
        • The Emory Clinic
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Northwestern Medicine
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21287
        • Johns Hopkins Hospital
    • Massachusetts
      • Charlestown, Massachusetts, Stati Uniti, 02129
        • Massachusetts General Hospital, MA
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Washington University School of Medicine
    • New York
      • New York, New York, Stati Uniti, 10032
        • Columbia University Medical center
    • Texas
      • Austin, Texas, Stati Uniti, 78756
        • Austin Neuromuscular Center
      • Umeå, Svezia, 90185
        • Norrlands Universitetssjukhus
    • Västerbotten County
      • Umeå, Västerbotten County, Svezia, 90185
        • University Hospital of Umea

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key Part A Inclusion Criteria:

  • Participants should have a protocol-defined rapidly progressive SOD1 mutation, confirmed by a central reader, or a SOD1 mutation that is approved for inclusion by an external mutation adjudication committee.
  • Participants with plasma NfL level less than the protocol-defined threshold.
  • Participants who are clinically presymptomatic for ALS (i.e., must not have clinically manifest ALS).

Key Part A Exclusion Criteria:

  • History or positive test result at screening for human immunodeficiency virus (HIV). The requirement for testing at Screening may be omitted if it is not permitted by local regulations.

  • Current hepatitis C infection [defined as positive Hepatitis C Virus (HCV) antibody and detectable HCV ribonucleic acid (RNA)]. Participants with positive HCV antibody and undetectable HCV RNA are eligible to participate in the study (United States Centers for Disease Control and Prevention).

  • Current hepatitis B infection (defined as positive for hepatitis B surface antigen (HBsAg) and/or anti-Hepatitis B Core antibody (HBc)). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-hepatitis B surface antibody (HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti- HBs) are eligible to participate in the study.

  • History of systemic hypersensitivity reaction to tofersen, the excipients contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study.

  • History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and/or is expected to be associated with elevations in NF, in the opinion of the Investigator.

  • Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that if not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding.

  • Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression

    ≤ 90 days of screening, which in the opinion of the Investigator would interfere with the study procedures.

  • Treatment with riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol (also known as ursodoxicoltaurine). If the participant has been on riluzole, edaravone, and/or sodium phenylbutyrate/taurursodiol, the medication(s) must be discontinued for at least 5 half-lives prior to Screening.

  • Use of off-label treatments for ALS.

  • Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.

  • Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication (e.g., clopidogrel) that cannot be safely continued or held for a Lumbar Puncture (LP) procedure, if necessary, according to local or institutional guidelines and/or Investigator determination.

  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment, biological agent, device, or approved therapy for investigational use. Participation in a noninterventional study focused on ALS natural history may be allowed at the discretion of the Investigator.

NOTE: Other protocol defined Inclusion/Exclusion criteria will apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Part A: Natural History Run-in

Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess NfL levels.

Sperimentale: Part B: Randomized, Double-Blind, Placebo-Controlled

Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive tofersen 100 milligrams (mg) or placebo via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to approximately 5.6 years.

Administered as specified in the treatment arm

Administered as specified in the treatment arm

Altri nomi:
  • BIIB067
  • QALSODIA
Sperimentale: Part C: Open-Label Extension

Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter up to the final maintenance dose visit. Participants who received tofersen during Part B will receive tofersen 100 mg on Days 1, 29, and every 28 days thereafter up to the final maintenance dose visit, with a dose of placebo on Day 15 to maintain the study blind. The combined duration of Part B and Part C is up to approximately 5.6 years.

Administered as specified in the treatment arm

Administered as specified in the treatment arm

Altri nomi:
  • BIIB067
  • QALSODIA
Sperimentale: Part D: Open-Label Treatment

Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will receive tofersen 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.

Administered as specified in the treatment arm

Altri nomi:
  • BIIB067
  • QALSODIA

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Lasso di tempo
Part B: Time to Emergence of Clinically Manifest ALS
Lasso di tempo: Up to 5.6 years
Up to 5.6 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Parti B e C: Percentuale di partecipanti con insorgenza di SLA clinicamente manifesta entro 24 mesi dal basale della Parte B
Lasso di tempo: Fino a 24 mesi
Fino a 24 mesi
Parti B e C: variazione rispetto al basale della capacità vitale lenta (SVC) percentuale prevista
Lasso di tempo: Fino a 5,6 anni
Fino a 5,6 anni
Parti B e C: percentuale di partecipanti con esito come decessi in base all'analisi del tempo intercorso fino alla morte
Lasso di tempo: Fino a 5,6 anni
Fino a 5,6 anni
Parti B, C e D: numero di partecipanti con eventi avversi (EA) ed eventi avversi gravi (SAE) durante il periodo di trattamento
Lasso di tempo: Parti B e C: fino a 5,6 anni e parte D: fino a 2 anni
Parti B e C: fino a 5,6 anni e parte D: fino a 2 anni
Parti B, C e D: variazione rispetto al basale delle concentrazioni plasmatiche di NfL
Lasso di tempo: Parti B e C: fino a 5,6 anni e parte D: fino a 2 anni
Parti B e C: fino a 5,6 anni e parte D: fino a 2 anni
Parti B, C e D: variazione delle concentrazioni di SOD1 nel liquido cerebrospinale totale (CSF).
Lasso di tempo: Parti B e C: fino a 5,6 anni e parte D: fino a 2 anni
Parti B e C: fino a 5,6 anni e parte D: fino a 2 anni
Parts B and C: Change in ALS Functional Rating Scale (ALSFRS-R) Total Score
Lasso di tempo: Up to 5.6 years

The ALSFRS-R measures 4 functional domains: respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 to 4, for a total possible score of 48, with higher scores representing better function.

Up to 5.6 years
Parts B and C: Percentage of Participants with Outcome as Death or Permanent Ventilation Based on Time to Death or Permanent Ventilation Analysis
Lasso di tempo: Up to 5.6 years

Permanent ventilation is defined as ≥22 hours of invasive or non-invasive mechanical ventilation per day for ≥21 consecutive days.

Up to 5.6 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Medical Director, Biogen

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 maggio 2021

Completamento primario (Stimato)

7 agosto 2027

Completamento dello studio (Stimato)

25 maggio 2028

Date di iscrizione allo studio

Primo inviato

20 aprile 2021

Primo inviato che soddisfa i criteri di controllo qualità

20 aprile 2021

Primo Inserito (Effettivo)

23 aprile 2021

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 233AS303
  • 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
  • 2023-505641-12 (Altro identificatore: EU Trial (CTIS) Number)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .